A citation-based method for searching scientific literature

Daniel J Brat, Kenneth Aldape, Howard Colman, Dominique Figrarella-Branger, Gregory N Fuller, Caterina Giannini, Eric C Holland, Robert B Jenkins, Bette Kleinschmidt-DeMasters, Takashi Komori, Johan M Kros, David N Louis, Catriona McLean, Arie Perry, Guido Reifenberger, Chitra Sarkar, Roger Stupp, Martin J van den Bent, Andreas von Deimling, Michael Weller. Acta Neuropathol 2020
Times Cited: 93







List of co-cited articles
671 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Daniel J Brat, Kenneth Aldape, Howard Colman, Eric C Holland, David N Louis, Robert B Jenkins, B K Kleinschmidt-DeMasters, Arie Perry, Guido Reifenberger, Roger Stupp,[...]. Acta Neuropathol 2018
248
59

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
54

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Mitsuaki Shirahata, Takahiro Ono, Damian Stichel, Daniel Schrimpf, David E Reuss, Felix Sahm, Christian Koelsche, Annika Wefers, Annekathrin Reinhardt, Kristin Huang,[...]. Acta Neuropathol 2018
127
36

cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading.
David N Louis, Pieter Wesseling, Kenneth Aldape, Daniel J Brat, David Capper, Ian A Cree, Charles Eberhart, Dominique Figarella-Branger, Maryam Fouladi, Gregory N Fuller,[...]. Brain Pathol 2020
104
36

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
Daniel J Brat, Roel G W Verhaak, Kenneth D Aldape, W K Alfred Yung, Sofie R Salama, Lee A D Cooper, Esther Rheinbay, C Ryan Miller, Mark Vitucci, Olena Morozova,[...]. N Engl J Med 2015
32

cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.
David N Louis, Caterina Giannini, David Capper, Werner Paulus, Dominique Figarella-Branger, M Beatriz Lopes, Tracy T Batchelor, J Gregory Cairncross, Martin van den Bent, Wolfgang Wick,[...]. Acta Neuropathol 2018
131
30

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
30

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
26

DNA methylation-based classification of central nervous system tumours.
David Capper, David T W Jones, Martin Sill, Volker Hovestadt, Daniel Schrimpf, Dominik Sturm, Christian Koelsche, Felix Sahm, Lukas Chavez, David E Reuss,[...]. Nature 2018
720
25

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
Michele Ceccarelli, Floris P Barthel, Tathiane M Malta, Thais S Sabedot, Sofie R Salama, Bradley A Murray, Olena Morozova, Yulia Newton, Amie Radenbaugh, Stefano M Pagnotta,[...]. Cell 2016
913
25

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
23

cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation.
David W Ellison, Cynthia Hawkins, David T W Jones, Arzu Onar-Thomas, Stefan M Pfister, Guido Reifenberger, David N Louis. Acta Neuropathol 2019
61
34

Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Kosuke Aoki, Hideo Nakamura, Hiromichi Suzuki, Keitaro Matsuo, Keisuke Kataoka, Teppei Shimamura, Kazuya Motomura, Fumiharu Ohka, Satoshi Shiina, Takashi Yamamoto,[...]. Neuro Oncol 2018
91
18

The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R Salama, Siyuan Zheng, Debyani Chakravarty, J Zachary Sanborn, Samuel H Berman,[...]. Cell 2013
18

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
Jeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L Kosel, Ivan V Smirnov,[...]. N Engl J Med 2015
938
17

CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.
Gerald F Reis, Melike Pekmezci, Helen M Hansen, Terri Rice, Roxanne E Marshall, Annette M Molinaro, Joanna J Phillips, Hannes Vogel, John K Wiencke, Margaret R Wrensch,[...]. J Neuropathol Exp Neurol 2015
60
26

cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC).
David N Louis, Pieter Wesseling, Werner Paulus, Caterina Giannini, Tracy T Batchelor, J Gregory Cairncross, David Capper, Dominique Figarella-Branger, M Beatriz Lopes, Wolfgang Wick,[...]. Acta Neuropathol 2018
53
30

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
17

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Romain Appay, Caroline Dehais, Claude-Alain Maurage, Agusti Alentorn, Catherine Carpentier, Carole Colin, François Ducray, Fabienne Escande, Ahmed Idbaih, Aurélie Kamoun,[...]. Neuro Oncol 2019
32
46

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
Dominik Sturm, Hendrik Witt, Volker Hovestadt, Dong-Anh Khuong-Quang, David T W Jones, Carolin Konermann, Elke Pfaff, Martje Tönjes, Martin Sill, Sebastian Bender,[...]. Cancer Cell 2012
16

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Roger Stupp, Sophie Taillibert, Andrew Kanner, William Read, David Steinberg, Benoit Lhermitte, Steven Toms, Ahmed Idbaih, Manmeet S. Ahluwalia, Karen Fink,[...]. JAMA 2017
571
15

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.
Quinn T Ostrom, Gino Cioffi, Haley Gittleman, Nirav Patil, Kristin Waite, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2019
563
15

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.
Adriana Olar, Khalida M Wani, Kristin D Alfaro-Munoz, Lindsey E Heathcock, Hinke F van Thuijl, Mark R Gilbert, Terri S Armstrong, Erik P Sulman, Daniel P Cahill, Elizabeth Vera-Bolanos,[...]. Acta Neuropathol 2015
175
13

IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Rui Ryan Yang, Zhi-Feng Shi, Zhen-Yu Zhang, Aden Ka-Yin Chan, Abudumijiti Aibaidula, Wei-Wei Wang, Johnny Sheung Him Kwan, Wai Sang Poon, Hong Chen, Wen-Cai Li,[...]. Brain Pathol 2020
16
81

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Roger Stupp, Monika E Hegi, Warren P Mason, Martin J van den Bent, Martin J B Taphoorn, Robert C Janzer, Samuel K Ludwin, Anouk Allgeier, Barbara Fisher, Karl Belanger,[...]. Lancet Oncol 2009
13

Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy.
David N Louis, Ken Aldape, Daniel J Brat, David Capper, David W Ellison, Cynthia Hawkins, Werner Paulus, Arie Perry, Guido Reifenberger, Dominique Figarella-Branger,[...]. Acta Neuropathol 2017
61
19

Mechanisms and therapeutic implications of hypermutation in gliomas.
Mehdi Touat, Yvonne Y Li, Adam N Boynton, Liam F Spurr, J Bryan Iorgulescu, Craig L Bohrson, Isidro Cortes-Ciriano, Cristina Birzu, Jack E Geduldig, Kristine Pelton,[...]. Nature 2020
101
12

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Martin J van den Bent, Brigitta Baumert, Sara C Erridge, Michael A Vogelbaum, Anna K Nowak, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Jean Francais Baurain, Warren P Mason,[...]. Lancet 2017
154
12

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
Jan C Buckner, Edward G Shaw, Stephanie L Pugh, Arnab Chakravarti, Mark R Gilbert, Geoffrey R Barger, Stephen Coons, Peter Ricci, Dennis Bullard, Paul D Brown,[...]. N Engl J Med 2016
436
12

Mutational landscape and clonal architecture in grade II and III gliomas.
Hiromichi Suzuki, Kosuke Aoki, Kenichi Chiba, Yusuke Sato, Yusuke Shiozawa, Yuichi Shiraishi, Teppei Shimamura, Atsushi Niida, Kazuya Motomura, Fumiharu Ohka,[...]. Nat Genet 2015
433
11

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.
Michael Weller, Martin van den Bent, Jörg C Tonn, Roger Stupp, Matthias Preusser, Elizabeth Cohen-Jonathan-Moyal, Roger Henriksson, Emilie Le Rhun, Carmen Balana, Olivier Chinot,[...]. Lancet Oncol 2017
439
11

A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Mark R Gilbert, James J Dignam, Terri S Armstrong, Jeffrey S Wefel, Deborah T Blumenthal, Michael A Vogelbaum, Howard Colman, Arnab Chakravarti, Stephanie Pugh, Minhee Won,[...]. N Engl J Med 2014
11

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Olivier L Chinot, Wolfgang Wick, Warren Mason, Roger Henriksson, Frank Saran, Ryo Nishikawa, Antoine F Carpentier, Khe Hoang-Xuan, Petr Kavan, Dana Cernea,[...]. N Engl J Med 2014
11

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.
Quinn T Ostrom, Haley Gittleman, Gabrielle Truitt, Alexander Boscia, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2018
744
11

Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
Damian Stichel, Azadeh Ebrahimi, David Reuss, Daniel Schrimpf, Takahiro Ono, Mitsuaki Shirahata, Guido Reifenberger, Michael Weller, Daniel Hänggi, Wolfgang Wick,[...]. Acta Neuropathol 2018
72
15

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
David E Reuss, Felix Sahm, Daniel Schrimpf, Benedikt Wiestler, David Capper, Christian Koelsche, Leonille Schweizer, Andrey Korshunov, David T W Jones, Volker Hovestadt,[...]. Acta Neuropathol 2015
267
10


Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Timothy F Cloughesy, Aaron Y Mochizuki, Joey R Orpilla, Willy Hugo, Alexander H Lee, Tom B Davidson, Anthony C Wang, Benjamin M Ellingson, Julie A Rytlewski, Catherine M Sanders,[...]. Nat Med 2019
334
10

Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
C Mircea S Tesileanu, Linda Dirven, Maarten M J Wijnenga, Johan A F Koekkoek, Arnaud J P E Vincent, Hendrikus J Dubbink, Peggy N Atmodimedjo, Johan M Kros, Sjoerd G van Duinen, Marion Smits,[...]. Neuro Oncol 2020
31
32

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, Joachim Peter Steinbach, Uwe Schlegel, Michael Sabel, Peter Hau, Rolf-Dieter Kortmann, Dietmar Krex, Oliver Grauer,[...]. Lancet 2019
136
10

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Michael Weller, Nicholas Butowski, David D Tran, Lawrence D Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A Goldlust, Fabio Iwamoto,[...]. Lancet Oncol 2017
376
10

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
Michael Weller, Ruthild G Weber, Edith Willscher, Vera Riehmer, Bettina Hentschel, Markus Kreuz, Jörg Felsberg, Ulrike Beyer, Henry Löffler-Wirth, Kerstin Kaulich,[...]. Acta Neuropathol 2015
158
10

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, Andreas von Deimling, Thierry Gorlia, Khê Hoang-Xuan, Alba A Brandes, Guy Kantor, Martin J B Taphoorn, Mohamed Ben Hassel,[...]. Lancet Oncol 2016
210
10

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
9

Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.
Patrick J Cimino, Michael Zager, Lisa McFerrin, Hans-Georg Wirsching, Hamid Bolouri, Bettina Hentschel, Andreas von Deimling, David Jones, Guido Reifenberger, Michael Weller,[...]. Acta Neuropathol Commun 2017
48
18

IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
David E Reuss, Yasin Mamatjan, Daniel Schrimpf, David Capper, Volker Hovestadt, Annekathrin Kratz, Felix Sahm, Christian Koelsche, Andrey Korshunov, Adriana Olar,[...]. Acta Neuropathol 2015
163
9

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
Patrick J Killela, Zachary J Reitman, Yuchen Jiao, Chetan Bettegowda, Nishant Agrawal, Luis A Diaz, Allan H Friedman, Henry Friedman, Gary L Gallia, Beppino C Giovanella,[...]. Proc Natl Acad Sci U S A 2013
848
9

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Gregory Cairncross, Meihua Wang, Edward Shaw, Robert Jenkins, David Brachman, Jan Buckner, Karen Fink, Luis Souhami, Normand Laperriere, Walter Curran,[...]. J Clin Oncol 2013
599
9

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
Martin J van den Bent, Alba A Brandes, Martin J B Taphoorn, Johan M Kros, Mathilde C M Kouwenhoven, Jean-Yves Delattre, Hans J J A Bernsen, Marc Frenay, Cees C Tijssen, Wolfgang Grisold,[...]. J Clin Oncol 2013
646
9

Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
Melike Pekmezci, Terri Rice, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Helen Hansen, Hugues Sicotte, Thomas M Kollmeyer, Lucie S McCoy, Gobinda Sarkar,[...]. Acta Neuropathol 2017
146
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.